Table 9.
IMbrave150 study: baseline characteristics (ITT) [modified from 47]
| Characteristic | Atezo + Beva (n = 336) | Sorafenib (n = 165) |
| Age, years | 64 (26–88) | 66 (33–87) |
| Male sex | 277 (82%) | 137 (83%) |
| Region | ||
| Asia (excluding Japan) | 133 (40%) | 68 (41%) |
| Rest of the world | 203 (60%) | 97 (59%) |
| ECOG PS 1 | 127 (38%) | 62 (38%) |
| Child-Pugh class | ||
| A | 333 (99%) | 165 (100%) |
| B | 1 (<1%) | 0 |
| Etiology of HCC | ||
| HBV | 164 (49%) | 76 (46%) |
| HCV | 72 (21%) | 36 (22%) |
| Nonviral | 100 (30%) | 53 (32%) |
| BCLC staging at study entry | ||
| A | 8 (2%) | 6 (4%) |
| B | 52 (15%) | 26 (16%) |
| C | 276 (82%) | 133 (81%) |
| AFP ≥400 ng/mL | 126 (38%) | 61 (37%) |
| EHS | 212 (63%) | 93 (56%) |
| MVI | 129 (38%) | 71 (43%) |
| EHS and/or MVI | 258 (77%) | 120 (73%) |
Figures are presented as median (range) or n (%). ITT, intention to treat; Atezo, atezolizumab; Beva, bevacizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; EHS, extrahepatic spread; MVI, macrovascular invasion.